GB0906159D0 - Drug combination for the treatment of proteostatic diseases - Google Patents

Drug combination for the treatment of proteostatic diseases

Info

Publication number
GB0906159D0
GB0906159D0 GBGB0906159.9A GB0906159A GB0906159D0 GB 0906159 D0 GB0906159 D0 GB 0906159D0 GB 0906159 A GB0906159 A GB 0906159A GB 0906159 D0 GB0906159 D0 GB 0906159D0
Authority
GB
United Kingdom
Prior art keywords
treatment
drug combination
proteostatic
diseases
proteostatic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0906159.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GBGB0906159.9A priority Critical patent/GB0906159D0/en
Publication of GB0906159D0 publication Critical patent/GB0906159D0/en
Priority to PCT/GB2010/000710 priority patent/WO2010116141A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0906159.9A 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases Ceased GB0906159D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0906159.9A GB0906159D0 (en) 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases
PCT/GB2010/000710 WO2010116141A2 (en) 2009-04-09 2010-04-07 Drug combination for the treatment of proteostatic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0906159.9A GB0906159D0 (en) 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases

Publications (1)

Publication Number Publication Date
GB0906159D0 true GB0906159D0 (en) 2009-05-20

Family

ID=40750361

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0906159.9A Ceased GB0906159D0 (en) 2009-04-09 2009-04-09 Drug combination for the treatment of proteostatic diseases

Country Status (2)

Country Link
GB (1) GB0906159D0 (en)
WO (1) WO2010116141A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
KR20140041505A (en) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. Tolerogenic Synthetic Nanocarriers for Regulatory B Cell Induction
HUE052599T2 (en) 2013-05-03 2021-05-28 Selecta Biosciences Inc Methods and compositions for enhancing cd4+ regulatory t cells
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (en) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol for the treatment of glucocerebrosidase-associated disorders
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN114207440A (en) 2019-06-04 2022-03-18 西莱克塔生物科技公司 PEGylated uricase formulations and dosages
KR20230128462A (en) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 Process for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
CN101541172A (en) * 2005-06-08 2009-09-23 阿米库斯治疗学公司 Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
JP5303458B2 (en) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド Method for treating neurological diseases by enhancing β-glucocerebrosidase activity
WO2008054947A2 (en) * 2006-10-02 2008-05-08 The Brigham And Women's Hospital, Inc. Structure of acid beta-glucosidase and methods for identifying therapeutic agents
EP2150254A4 (en) * 2007-04-26 2010-11-10 Amicus Therapeutics Inc Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009049422A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
EP2252288A1 (en) * 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
EP2323652A2 (en) * 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases

Also Published As

Publication number Publication date
WO2010116141A2 (en) 2010-10-14
WO2010116141A3 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
IL259475A (en) Combination therapy for the treatment of diabetes
IL219073A (en) Pharmaceutical combination for treatment of cancer
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
IL216509A0 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA201301601B (en) Treatment of diseases
EP2166837A4 (en) Drug combination for the treatment of skin disorders
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
GB0908193D0 (en) Treatment of disease state
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
IL241253A0 (en) Peptides for the treatment of neurodegenerative diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
IL213606A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
IL216717A (en) Use of benzydamine in the manufacture of a medicament for the treatment of p40-dependent diseases
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases
GB0908666D0 (en) Treatment of proteostatic disease
GB0920651D0 (en) Molecular methods for the treatment of disease
GB0819543D0 (en) Treatment of proteostatic disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)